Clinical trial
Phase II Study of 99mTc-glucarate in Chest Pain Patients Suspected With ACS With no Obvious Signs of AMI and With Known Previous CAD.
NCT00614354 is registered in ClinicalTrials.gov with Molecular Targeting Technologies, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of 99mTc-glucarate in Chest Pain Patients Suspected With ACS With no Obvious Signs of AMI and With Known Previous CAD.
- Lead sponsor
- Molecular Targeting Technologies, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2008
- Completion date
- September 30, 2010
- Enrollment
- 66 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
Lead sponsor's other trials
Molecular Targeting Technologies, Inc., most recent start first.
Similar trials
Same condition (Acute Coronary Syndrome) and phase, most recent start first.
+58 more trials See the condition page